You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萊美藥業(300006.SZ):取得鹽酸納洛酮注射液(規格:1ml:1mg和2ml:2mg)的藥品補充申請批準通知書

格隆匯5月12日丨萊美藥業(300006.SZ)公佈,近日,重慶萊美藥業股份有限公司收到國家藥品監督管理局覈準簽發的鹽酸納洛酮注射液1ml:1mg和2ml:2mg兩種規格《藥品補充申請批準通知書》。

鹽酸納洛酮注射液爲阿片類受體拮抗藥,主要適應症如下:用於阿片類藥物複合麻醉術後,拮抗該類藥物所致的呼吸抑制,促使病人甦醒;用於阿片類藥物過量,完全或部分逆轉阿片類藥物引起的呼吸抑制;用於解救急性乙醇中毒;用於急性阿片類藥物過量的診斷。

作爲一款在臨牀應用多年的急救藥物,鹽酸納洛酮注射液已被納入2024版國家醫保甲類藥目錄。根據藥融雲數據顯示,鹽酸納洛酮注射液2022年-2024年上半年在中國醫院(全終端)市場銷售額分別爲4.20億元、5.59億元、2.64億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account